GAINESVILLE, Fla.--(BUSINESS WIRE)--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today reported its financial results for the full year 2023 and provided a business update. “We made significant progress over the course of the past year. We continue to be extremely active with the NPC patient and scientific ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Commission file number 0-25466 CYCLO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) | Nevada | 59-3029743 | | --- | --- | | (State or other jurisdiction of | (IRS Employer | | incorporation or organization) | Identification No.) | | 6714 NW 16th Street, Suite B, | | | Gainesville, Florida | 32653 | | (Address of principal executive offices) | (Zip Code) | Registrant's telephone number, including area ...

GAINESVILLE, Fla.--(BUSINESS WIRE)--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today announced the United States Patent and Trademark Office (USPTO) has granted U.S. Patent No. 11,925,659 titled, “Methods for Treating Alzheimer’s Disease,” with claims that cover the use of Trappsol® Cyclo™ for the preventio ...

GAINESVILLE, Fla.--(BUSINESS WIRE)--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today announced that the Company received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) regarding Cyclo Therapeutics’ U.S. Patent Application No. 17/289,137 titled, “Methods for Treating Alzheim ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 10-Q ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended: September 30, 2023 or ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from ____ to ____ Commission file number: 0-25466 CYCLO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) | Nevada | 59-3029743 | | --- | --- | ...

Financial Performance - Net losses for Q2 2023 were $4,636,455, compared to $3,451,990 in Q2 2022, representing a 34% increase in losses [111]. - Total revenues for Q2 2023 decreased by 78% to approximately $117,000, down from approximately $542,000 in Q2 2022 [112]. - Sales of Trappsol® Cyclo™ for Q2 2023 were approximately $58,000, a significant increase from $700 in Q2 2022 [112]. - Sales of Trappsol® HPB decreased by 84% in Q2 2023 to approximately $57,000 from approximately $357,000 in Q2 2022 [113]. - Cost of products sold for Q2 2023 decreased by 73% to approximately $20,000 from approximately $74,000 in Q2 2022 [117]. Research and Development - Research and development expenses increased by 69% to approximately $3,170,000 for Q2 2023, up from approximately $1,874,000 in Q2 2022 [121]. - Research and development expenses as a percentage of total operating expenses rose to 66% for the first half of 2023, compared to 42% in the same period of 2022 [121]. Expenses and Cash Flow - Personnel expenses decreased by 19% to approximately $785,000 for Q2 2023 from approximately $971,000 in Q2 2022 [120]. - Professional fees decreased by 36% to approximately $414,000 for Q2 2023, compared to approximately $650,000 in Q2 2022 [122]. - Cash decreased to $841,530 as of June 30, 2023, compared to $1,543,418 as of December 31, 2022 [125]. - Cash used in operations was approximately $7,849,000 for the six months ended June 30, 2023, compared to approximately $9,186,000 for the same period in 2022 [125]. Working Capital and Financing - Negative working capital was approximately $1,550,000 as of June 30, 2023, compared to positive working capital of approximately $678,000 at December 31, 2022 [125]. - The company will need to raise additional capital in the future to support ongoing operations and clinical trials [126]. - The ability to continue as a going concern is dependent upon the availability of equity financing [127]. Tax and Accounting - The company has approximately $42,395,000 in net state and federal operating loss carryforwards expiring from 2024 through 2037 [128]. - A 100% valuation allowance has been provided on the deferred tax asset based on expected future expenses related to clinical trials and development initiatives [128]. - There were no off-balance sheet arrangements as of June 30, 2023 [129]. - No significant changes to critical accounting policies occurred during the quarter ended June 30, 2023 [132].

| Nevada | 59-3029743 | | --- | --- | | (State or other jurisdiction of | (IRS Employer | | incorporation or organization) | Identification No.) | | 6714 NW 16th Street, Suite B, Gainesville, Florida | 32653 | | (Address of principal executive offices) | (Zip Code) | UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 10-Q ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended: March 31, 2023 or ☐ Transition Report P ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark one) ☒ Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended December 31, 2022 ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the period from ____________ to ___________ Commission file number 0-25466 CYCLO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Nevada 59-3029743 (State or other juri ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 10-Q ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended: September 30, 2022 or ☐Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from ____ to ____ Commission file number: 0-25466 CYCLO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) | --- | --- | |------------------------ ...

NASDAQ: CYTH cyclotherapeutics.com Corporate Presentation 2 Forward-Looking Statements Some of the information in this presentation relates to future events or future business and financial performance. Such statements constitute forward-looking information within the meaning of the Private Securities Litigation Act of 1995. Such statements can be only predictions and the actual events or results may differ from those discussed due to, among other things, the risks described in the public filings and other ...